Prof Dr Monique Minnema was trained as internist and hematologist at Academic Medical Center, Amsterdam and the University Medical Center, Utrecht. She started working as a hematologist in 2005 at the department of hematology, UMC Utrecht and was appointed full professor in 2019. She is specialized in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasis like Multiple Myeloma, AL amyloidosis, and Waldenstrom Macroglobulinemia. Prof Minnema is author on several national and internatonial quidelines on the diagnosis and treatment of these diseases.
She is head supervisor of the hematology clinical research team, the hematology biobank and the European expertise reference network (ERN) malignant hematology of the UMC Utrecht. Her main focus of clinical research is the development of novel therapies (both cellular and drug) for plasma cell dyscrasias and the development of new research structures for hematology research in the Netherlands.

Prof Dr Minnema is vice chairperson of the HOVON working partie for Multiple
Myeloma, and member of the Lymphoma and IEC working parties. Examples of her work are the HOVON 104 trial and the use of the monoclonal antibody Daratumumab for patients with AL amyloidosis in first line treatment, the clinical studies with Daratumumab and the bispecific antibody Talquetamab in relapsed Multiple Myeloma the use of anti CD19 CAR T cells in relapsed Lymphoma. Her translational research focuses on 3D models to predict response to therapy and the use of combined immunotherapy for relapsed multiple myeloma.

She was a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016, and is co initiator of the yearly Immune Effector Cell Symposium and the current chair of the Systemic Amyloidosis symposium in the Netherlands

Memberships:

• NIV
• NVvH
• ASH
• EHA
• ISA

Stichting Transparantieregister Zorg - Home, BIG 59043578201